Skip to Content
Søk Menu

ASCO 2019: New promising drug for second-line SCLC patients

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relateret indhold

Vivi Quoc Nguyen

Carboplatin is a Viable Option in Treating Patients with Completely Resected Non-Small Cell Lung Cancer

/ Vivi Quoc Nguyen
Lungekreft Play the Video 1:44
Odd Terje Brustugun

Onkologisk Forum: Highlights in Lung Cancer Treatment

/ Odd Terje Brustugun
LungekreftOnkologiskForum23 Play the Video 5:22
Nathan Harrison

Interventions Designed to Reduce Lung Cancer Stigma

/ Nathan Harrison
LungekreftWCLC23 Play the Video 7:15
Jonathan Spicer

Perioperative Pembrolizumab Shows Significant OS in ResectableNon-Small-Cell Lung Cancer

/ Jonathan Spicer
ESMO23Lungekreft Play the Video 4:01
Masahiro Tsuboi

Efficacy of Osimertinib in resected EGFR-Mutated stage IB-IIIA NSCLC

/ Masahiro Tsuboi
Lungekreft Play the Video 7:07

WCLC 2023 – NSCLC: New Data on Perioperative Immunotherapy Treatment 

/ BestPractice Nordic
ImmunterapiLungekreftNSCLCWCLC23

Adjuvant treatment with 3rd generation EGFR-TKI can increase progression-free survival 

/ BestPractice Nordic
LungekreftNSCLCWCLC23

CheckMate 227: 6-year data on the treatment of locally advanced NSCLC with Opdivo and Yervoy  

/ BestPractice Nordic
LungekreftNSCLCWCLC23

Adjuvant Osimertinib – New Standard of Care for Patients with Resected EGFR-mutated NSCLC

/ BestPractice Nordic
ASCO23Lungekreft
Back to top